BOSTON, Massachusetts, Sept. 3 -- Harvard Medical School issued the following news:

An experimental medication shows promise in slowing the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to recently released results from a clinical trial run by Harvard Medical School investigators based at Massachusetts General Hospital and colleagues at Amylyx Pharmaceuticals, the company that manufactures the medication and that helped fund the study.

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:

What's your Affiliation

Government Newspaper / Media Business Public Policy Individual / Student Educators

Email:

Phone:

Organization, if any:

State/Country you are in:

Additional questions or comments:

Submit Form Click here for more information about our products